Sugi Predict

Sugi Predict / Compounds / SCHEMBL668678

SCHEMBL668678

SCHEMBL668678

CC(C)(C)c1cc(NC(=O)Nc2ccc(Sc3ccncc3)cc2)no1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 8/20 0.73
▸ RAF1 P04049 7/20 0.71
▸ RIPK2 O43353 1/20 0.71
▸ MAPK14 Q16539 3/20 0.66
▸ MEN1 O00255 1/20 0.65
▸ NPC1 O15118 1/20 0.65
▸ RAB9A P51151 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ CSF1R P07333 1/20 0.61
▸ MAPK13 O15264 1/20 0.60
▸ MAPK12 P53778 1/20 0.60
▸ MAPK11 Q15759 1/20 0.60
▸ KDR P35968 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668089 0.89 MEN1 (0.63) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL13234454 0.89 FLT3 (0.83) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL667543 0.86 FLT3 (0.61) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL13234438 0.85 MAPK14 (0.72) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL13234373 0.84 FLT3 (1.00) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL667804 0.84 FLT3 (0.59) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL668459 0.83 RAF1 (1.00) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL667635 0.83 RAF1 (1.00) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL1846033 0.83 FLT3 (0.56) FLT3RAF1RIPK2MAPK14MEN1
SCHEMBL1846031 0.82 FLT3 (0.55) FLT3RAF1RIPK2MAPK14MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149706-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS DUMAS JACQUES (US) 2012-06-14 — — US claimed
US-20120046290-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2012-02-23 — — US claimed
US-7838541-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE, LLC (US) 2010-11-23 — — US claimed
JP-4403482-B2 — — 2010-01-27 — — JP claimed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 — — US claimed
EP-1041982-A4 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS BAYER PHARMACEUTICALS CORP (US) 2006-06-14 — — EP claimed
EP-1047418-B1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER PHARMACEUTICALS CORP (US) 2005-07-27 — — EP claimed
JP-2001526223-A — — 2001-12-18 — — JP claimed
EP-1041982-A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS Bayer Corporation (US) 2000-10-11 — — EP claimed
WO-1999032111-A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 — — WO claimed
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2020-05-19 — — US disclosed
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2018-10-18 — — US disclosed
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2016-01-21 — — US disclosed
US-8618141-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE LLC (US) 2013-12-31 — — US disclosed
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2012-11-15 — — US disclosed
EP-1047418-B1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER PHARMACEUTICALS CORP (US) 2005-07-27 — — EP disclosed
CN-1544420-A Inhibition of raf kinase using substituted heterocyclic ureas — 2004-11-10 — — CN disclosed
EP-1047418-A4 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER AG (US) 2001-02-07 — — EP disclosed
EP-1047418-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS Bayer Corporation (US) 2000-11-02 — — EP disclosed
WO-1999032106-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149706-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS MAPK1, MAP3K1, MAP3K7 FLT3 167/4885RAF1 155/4885RIPK2 792/4885
US-20120046290-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS MAPK1, MAP3K1, MAP3K7 FLT3 167/4885RAF1 155/4885RIPK2 792/4885
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR FLT3 200/4885RAF1 867/4885RIPK2 3703/4885
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity FLT1, FLT4, KDR FLT3 200/4885RAF1 867/4885RIPK2 3703/4885
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF FLT3 131/4885RAF1 2/4885RIPK2 483/4885
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY FLT4, FLT1, KDR FLT3 140/4885RAF1 817/4885RIPK2 3498/4885
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR FLT3 200/4885RAF1 867/4885RIPK2 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.